Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. - Wikidata - awgldk - TriplyDB

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.

http://www.wikidata.org/entity/Q34624487

about

Aflibercept for neovascular age-related macular degeneration Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis Molecularly targeted drugs for metastatic colorectal cancer Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interi Co-opting biology to deliver drugs Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity Ziv-aflibercept in macular disease.Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related Macular Degeneration With OCT Segmentation Volumetric Analysis.Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD.Bevacizumab for neovascular age-related macular degeneration in Chinese patients in a clinical setting.Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration.The role of Aflibercept in the management of age-related macular degeneration.Introduction. Treatment paradigms within the use of anti-VEGF agents.Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia.Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study.Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD

P2860

Q24186157-A93F36F6-2097-442A-B7D9-5CA8A1316BE1 Q26785646-4637655D-BEA6-4556-9E1E-0417E1D4B60A Q26828735-EE2AA772-725D-4C4E-B503-7C527B89E70F Q33633742-1928FDEA-BE27-47AB-98A1-4CEDD8252879 Q33659405-D05DBC15-D0EC-44A2-A4CF-97C23C35523C Q34424045-AA77D631-590F-4A53-A2CB-499E5EF79DC1 Q35043903-F4BDB5EE-EBA3-4FC9-85C8-A8C82B6C5374 Q35604265-9345B497-9E88-4B46-94C3-7E4BEAA2B49F Q35899591-4DFDA2CF-28F0-4D16-AA69-1388DA730E1A Q35960521-1D332711-A340-4ED4-9784-14C1045D241A Q36395332-1E91FA16-2DE9-410C-858A-50C2D356CF82 Q36832971-CD2C0801-1E37-4DD7-96F3-F8C31A245E7F Q37702363-E9762E38-3AE1-4579-8D1C-E4C02110F0BC Q38777050-38548C9E-A94F-46C1-BB41-5AE62BAD8E30 Q42588556-055F4998-0774-4166-8562-04F7EE7364BF Q47124190-C4575056-6F5D-4B86-ADA9-DC75C9B835AD Q53704361-711C5139-10D8-45C3-BEDA-CE7403EB03FF Q58799603-41EDBC8F-E0D5-4526-B1F1-61F0EA629121

P2860

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.

http://www.wikidata.org/entity/Q34624487

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Comparative effectiveness of a ...... -related macular degeneration.

@ast

Comparative effectiveness of a ...... -related macular degeneration.

@en

Comparative effectiveness of a ...... -related macular degeneration.

@nl

type

label

Comparative effectiveness of a ...... -related macular degeneration.

@ast

Comparative effectiveness of a ...... -related macular degeneration.

@en

Comparative effectiveness of a ...... -related macular degeneration.

@nl

prefLabel

Comparative effectiveness of a ...... -related macular degeneration.

@ast

Comparative effectiveness of a ...... -related macular degeneration.

@en

Comparative effectiveness of a ...... -related macular degeneration.

@nl

P1433

Q34624487-9B7BA9BC-CA6A-4201-B176-0208BCCA3603

P1476

Q34624487-37B0F364-4933-4048-BDA8-6F42AE8A877B

P2093

Q34624487-63CE603A-0A33-41FC-917F-D0A387235F7F

Q34624487-65C67EAC-0813-4C3F-AFB1-5E912B394281

Q34624487-F75F307B-2D41-49CD-BD0A-F867E9EEC32F

P2860

Q34624487-14A163E1-BA10-415D-999B-E9F71A0916E7

Q34624487-26E0262C-16E6-4956-A85C-984CBD68FE53

Q34624487-3681A9F0-F442-4115-B828-D188256F662E

Q34624487-370D7331-C5EE-4491-A9F9-52D820AD2E84

Q34624487-37336AE8-D6A2-48E7-9FC5-20552ADBFB57

Q34624487-3AB5D3F0-384E-42D6-8A60-444527E18FAF

Q34624487-434F8FDD-7276-48F1-AEEC-18AAE3B6504A

Q34624487-4BEE5B72-2A45-4B68-B6AA-47767E4DE15E

Q34624487-4FAE7A6C-C4D2-469F-B81A-215202F1C85B

Q34624487-6158F320-300E-49F5-9CD8-727B22B97525

P304

Q34624487-640451FD-533B-4B75-B009-89502D82DCC8

P31

Q34624487-7C7C3F1C-C647-49A2-BD4C-AD95E5B45F80

P356

Q34624487-FCB44821-E42C-45F7-939B-A4EEE5D9AF98

P407

Q34624487-7E778BCE-2221-4397-8996-026817AAC1DB

P478

Q34624487-A6FEA8EC-A0F0-4521-B7DE-28B78E452046

P577

Q34624487-D6579219-FB00-4680-A00C-33CE7DB5331C

P698

Q34624487-54301858-3D31-45FB-B5BE-056D3E9E0DE7

P921

Q34624487-3493FDA0-6EF3-4375-949A-E873F20C48C9

P932

Q34624487-C648FEB8-156A-4ACE-904E-59C6D43B5730

P356

P1433

Clinical Ophthalmology

P1476

Comparative effectiveness of a ...... -related macular degeneration.

@en

P2093

Michael Thomas

http://www.w3.org/2001/XMLSchema#string

Shaker A Mousa

http://www.w3.org/2001/XMLSchema#string

Shaymaa S Mousa

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.

Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates.

The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.

Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.

Evidence for anti-VEGF treatment of diabetic macular edema.

The activity of G-ROS and the predominant role of Type II reaction in the photodynamic therapy using 9-hydroxypheophorbide-α for HeLa cell lines.

Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept.

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab

P304

495-501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OPTH.S29974

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23503202

http://www.w3.org/2001/XMLSchema#string

P921

P932

3595183

http://www.w3.org/2001/XMLSchema#string